Olanzapine for young PEople with aNorexia nervosa: An open-label feasibility study to test recruitment, treatment acceptance, adherence, safety, outcome measures and patients' experience to prepare for a randomised placebo-controlled trial (OPEN)

奥氮平似乎是治疗神经性厌食症(AN)的一种有效且安全的药物，但它并未被批准用于AN。我们将对70名AN患者(澳大利亚15名，英国50名，年龄：12-24岁)进行初步研究，他们可以安全地服用奥氮平，但在专家护理下体重没有增加到足够的程度或AN症状得到改善。我们将对奥氮平在AN中的可接受性和可行性进行研究。患者将在8周和16周、6个月和12个月后进行检查。

Olanzapine seems to be a helpful and safe medication in anorexia nervosa (AN), but it is not approved for AN. We will perform a preliminary study with 70 patients with AN (15 in Australia and 50 in the UK, age: 12-24 years) who can safely take olanzapine and have not gained sufficient weight or experienced improvement in their AN symptoms under specialist care. We will the acceptability and feasibility of olanzapine in AN. Patients will be examined after 8 and 16 weeks, 6 months and 12 months.